Seth A. Reasoner

Seth A. Reasoner

Auto-generated profile, based on publicly available information

Seth A. Reasoner

Division of Molecular Pathogenesis, Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JVJessica Vincent
Jessica Vincent
CACarolina Adura
Carolina Adura
PGPu Gao
Pu Gao
ALAntonio Luz
Antonio Luz
LLLodoe Lama
Lodoe Lama
MAManuel Ascano
Manuel Ascano
Cyclic GMP-AMP synthase is essential for innate immunity against infection and cellular damage, serving as a sensor of DNA from pathogens or mislocalized self-DNA. Upon binding double-stranded DNA, cyclic GMP-AMP synthase synthesizes a cyclic dinucleotide that initiates an inflammatory cellular response. Mouse studies that recapitulate causative mutations in the autoimmune disease Aicardi-Goutières syndrome demonstrate that ablating the cyclic GMP-AMP synthase gene abolishes the deleterious phenotype. Here, we report the discovery of a class of cyclic GMP-AMP synthase inhibitors identified by a high-throughput screen. These compounds possess defined structure-activity relationships and we present crystal structures of cyclic GMP-AMP synthase, double-stranded DNA, and inhibitors within the enzymatic active site. We find that a chemically improved member, RU.521, is active and selective in cellular assays of cyclic GMP-AMP synthase-mediated signaling and reduces constitutive expression of interferon in macrophages from a mouse model of Aicardi-Goutières syndrome. RU.521 will be useful toward understanding the biological roles of cyclic GMP-AMP synthase and can serve as a molecular scaffold for development of future autoimmune therapies.

6 May 2020 in Molecular Cell
Verified
Journal Article
Closed access
BKByungil Kim
Byungil Kim
SASarah Arcos
Sarah Arcos
KRKatherine Rothamel
Katherine Rothamel
JJJeffrey Jian
Jeffrey Jian
KRKristie L. Rose
Kristie L. Rose
MAManuel Ascano
Manuel Ascano

30 April 2019 in mBio
Verified
Journal Article
Open access
PDF file
CBConnor J. Beebout
Connor J. Beebout
AEAllison R. Eberly
Allison R. Eberly
SWSabrina H. Werby
Sabrina H. Werby
SRSeth A. Reasoner
Seth A. Reasoner
JBJohn R. Brannon
John R. Brannon
MHMaria Hadjifrangiskou
Maria Hadjifrangiskou
Biofilms are multicellular bacterial communities encased in a self-secreted extracellular matrix comprised of polysaccharides, proteinaceous fibers, and DNA. Organization of these components lends spatial organization in the biofilm community. Here we demonstrate that oxygen gradients in uropathogenic Escherichia coli (UPEC) biofilms lead to spatially distinct expression programs for quinol oxidases—components of the terminal electron transport chain. Our studies reveal that the cytochrome bd -expressing subpopulation is critical for biofilm development and matrix production. In addition, we show that quinol oxidases are heterogeneously expressed in planktonic populations and that this respiratory heterogeneity provides a fitness advantage during infection. These studies define the contributions of quinol oxidases to biofilm physiology and suggest the presence of respiratory bet-hedging behavior in UPEC.

21 August 2025 in Journal of Bacteriology
Verified
Journal Article
Open access
SRSeth A. Reasoner
Seth A. Reasoner
JFJamisha Francis
Jamisha Francis
MHMaria Hadjifrangiskou
Maria Hadjifrangiskou
The human urinary tract, once presumed to be sterile, has emerged as a new frontier of microbial ecology. Recent advancements in high-throughput sequencing technologies have revealed the complexity and diversity of microbial communities that reside within the urinary tract. This mini-review discusses the prominent bacteria identified in the urinary microbiome and their correlations with various urologic conditions. This review serves to summarize the current state of urobiome research and chart a path for ongoing discovery. Additionally, we address the methodological challenges in urinary microbiome research, emphasizing the need for standardization in study protocols and the refinement of bioinformatics tools. We highlight that although differences in urobiome composition have been described for various urologic diseases. Similarly, the pathophysiologic source and consequences of those differences remain uncertain. We outline the steps to move urobiome research from descriptive to mechanistic studies, emphasizing rigorous study design, integrating multi-omics approaches, and developing robust model systems for experimental investigation. Finally, we outline critical questions for future investigation aimed at elucidating the intricate connections between the urinary microbiome and host health.

14 February 2024 in mBio
Verified
Journal Article
Open access
SRSeth A. Reasoner
Seth A. Reasoner
RBRachel Bernard
Rachel Bernard
AWAdam Waalkes
Adam Waalkes
KPKelsi Penewit
Kelsi Penewit
JLJanessa Lewis
Janessa Lewis
MNMaribeth Nicholson
Maribeth Nicholson
Cystic fibrosis (CF) is an autosomal recessive disease with significant gastrointestinal symptoms in addition to pulmonary complications. Recently approved treatments for CF, CF transmembrane conductance regulator (CFTR) modulators, are anticipated to substantially improve the care of people with CF and extend their lifespans. Prior work has shown that the intestinal microbiome correlates with health outcomes in CF, particularly in children. Here, we study the intestinal microbiome of children with CF before and after the CFTR modulator, ELX/TEZ/IVA. We identify promising improvements in microbiome diversity, reduced measures of intestinal inflammation, and reduced antibiotic resistance genes. We present specific bacterial taxa and protein groups which change following ELX/TEZ/IVA. These results will inform future mechanistic studies to understand the microbial improvements associated with CFTR modulator treatment. This study demonstrates how the microbiome can change in response to a targeted medication that corrects a genetic disease.

23 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JVJessica Vincent
Jessica Vincent
CACarolina Adura
Carolina Adura
PGPu Gao
Pu Gao
ALAntonio Luz
Antonio Luz
LLLodoe Lama
Lodoe Lama
MAManuel Ascano
Manuel Ascano
The previously published version of this Article contained errors in Fig. 6. In panel h the units of the x axis were incorrectly given as mM and should have been given as µM. Also, the IC50s for RU.365, RU.332 and RU.521 within panel h were incorrectly given as mM and should have been given as µM. These errors have been corrected in both the PDF and HTML versions of the Article.